IHAT-02 is under clinical development by Nemysis and currently in Phase III for Iron Deficiency Anemia. According to GlobalData, Phase III drugs for Iron Deficiency Anemia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how IHAT-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IHAT-02 overview

IHAT-02 is under development for the treatment of iron deficiency anemia. It is administered through oral route. It comprises of iron hydroxide adipate tartrate a nano-Fe(III) ferritin-mimetic.

Nemysis overview

Nemysis Limited is developing an extremely interesting portfolio of IP protected, science-based compounds and products which could be expeditiously brought to market as prescription Medical Foods, for the management of external triggers such as prolamins, and of conduct disorder (CD) symptoms, paying also attention to the increasing incidence of non-coeliac gluten sensitivity (NCGS).

For a complete picture of IHAT-02’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.